Proven survival benefit in first-line metastatic breast cancer

Herceptin has been shown to increase overall survival when given in combination with chemotherapy in women with HER2-positive MBC compared to chemotherapy alone.

Herceptin in combination with taxanes improves overall survival

Data from two pivotal trials of Herceptin in combination with taxanes – HO648g and M77001 – have established Herceptin as the foundation of care in first-line MBC.^1-3

First-line Herceptin extends progression-free survival in combination with an aromatase inhibitor

The Phase III TAnDEM trial demonstrated the benefit of combining Herceptin with an aromatase inhibitor (anastrozole) in post-menopausal women with HER2/hormone receptor co-positive disease. It showed that the addition of Herceptin to hormonal therapy doubles the median progression-free survival.

Herceptin in combination with other chemotherapies

Trials of Herceptin in combination with vinorelbine, gemcitabine and Xeloda have yielded high activity in HER2-positive MBC, both as first-line therapy and in pretreated disease.